Clinical Trials Logo

Clinical Trial Summary

The purpose of the current study is to evaluate the cerebral tissue oxygenation of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03172429
Study type Observational [Patient Registry]
Source University of Zurich
Contact
Status Completed
Phase
Start date May 24, 2017
Completion date August 16, 2017

See also
  Status Clinical Trial Phase
Completed NCT05264324 - Maximal Exercise Capacity at 2500 m of High Altitude N/A
Completed NCT05089487 - Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension N/A
Completed NCT05107700 - Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m N/A
Completed NCT05131737 - Exercise Endurance Time on the 2nd Day at 2500 m High Altitude N/A
Completed NCT05112172 - Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m N/A
Completed NCT03165019 - Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
Completed NCT03165032 - Right Ventricular Function During Exercise in Highlanders/Lowlanders
Completed NCT03165656 - Right Ventricular Function at Rest in Highlanders/Lowlanders
Completed NCT01566565 - The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Phase 1
Completed NCT01621061 - Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders N/A
Completed NCT01530464 - The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Phase 1